New hope for rare blood disorder: drug targets overactive immune cells

NCT ID NCT03801434

Recruiting now Disease control Sponsor: William Shomali Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing the drug ruxolitinib in people with hypereosinophilic syndrome, a rare condition where the body produces too many eosinophils (a type of white blood cell), causing organ damage. The study aims to see if ruxolitinib can normalize blood cell counts and reduce symptoms. Ten participants are being recruited, and the main goal is to measure how many respond to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ruxolitinib (a drug that blocks certain enzymes to reduce abnormal immune cell activity)
What this could lead to: If successful, this could provide a new treatment option for people with hypereosinophilic syndrome who do not respond to or cannot tolerate current therapies.
What could go wrong: This is a small, early-phase trial with only 10 participants, so results may not apply broadly. The drug may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BCR-JAK2 FUSION PROTEIN EXPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic eosinophilic leukemia Eosinophilia Hepatomegaly hypereosinophilic syndrome idiopathic hypereosinophilic syndrome lymphocytic hypereosinophilic syndrome myeloid/lymphoid neoplasm associated with JAK2 rearrangement Splenomegaly

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BCR-JAK2 FUSION PROTEIN EXPRESSION BLASTS 20 PERCENT OR LESS OF PERIPHERAL BLOOD WHITE CELLS BLASTS MORE THAN 5 PERCENT OF BONE MARROW NUCLEATED CELLS BLASTS MORE THAN 5 PERCENT OF PERIPHERAL BLOOD WHITE CELLS BLASTS UNDER 20 PERCENT OF BONE MARROW NUCLEATED CELLS CHRONIC EOSINOPHILIC LEUKEMIA, NOT OTHERWISE SPECIFIED EOSINOPHILIA HEPATOMEGALY HYPEREOSINOPHILIC SYNDROME JAK2 GENE MUTATION SPLENOMEGALY TEL-JAK2 FUSION PROTEIN EXPRESSION

Contacts and locations

Locations

Fred Hutchinson cancer research center
TERMINATED

Seattle, Washington, 98109, United States
OHSU Knight Cancer Institute
TERMINATED

Portland, Oregon, 97201, United States
Stanford Cancer Institute Palo Alto
RECRUITING

Palo Alto, California, 94304, United States
University of Utah
TERMINATED

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.